Rajul Jain
Directeur/Bestuurslid bij Innoskel SASU
Profiel
Rajul Jain, M.D.
is a Managing Director at Vida Ventures and physician-scientist by background.
Previously, Rajul was at Amgen where his last role was Global Development Lead.
There he oversaw the development of small molecules and biologics in the oncology and bone health therapeutic areas and was instrumental in advancing the R&D pipeline including regulatory approvals of Xgeva and Prolia.
Rajul completed his BA in chemistry and biochemistry at Rice University, and MD and Internal Medicine internship and residency at UT Southwestern Medical school, where he was a Howard Hughes Fellow.
He completed his post-doctoral training in biophysics at Rockefeller University, and fellowship training at MD Anderson Cancer Center, where he was Chief Fellow.
Rajul serves on the Board of Directors of Capstan Therapeutics, InnoSkel, LocanaBio, and Neogene Therapeutics.
Rajul was previously a volunteer Attending Physician treating underserved patients at UCLA Harbor Medical Center and continues to lecture regularly at UCLA.
Actieve functies van Rajul Jain
| Bedrijven | Functie | Begin |
|---|---|---|
Innoskel SASU
 Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Directeur/Bestuurslid | - |
VV Manager LLC
 VV Manager LLC Investment ManagersFinance VV Manager LLC (Vida Ventures) is a venture capital firm founded in 2017 by Arie Belldegrun, Arjun Goyal and Stefan Vitorovic. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | - |
Capstan Therapeutics, Inc.
 Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | Directeur/Bestuurslid | - |
Locanabio, Inc.
 Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | Directeur/Bestuurslid | - |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Health Technology |
VV Manager LLC
VV Manager LLC Investment ManagersFinance VV Manager LLC (Vida Ventures) is a venture capital firm founded in 2017 by Arie Belldegrun, Arjun Goyal and Stefan Vitorovic. The firm is headquartered in Boston, Massachusetts. | Finance |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | Commercial Services |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | Technology Services |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Health Technology |